Case Reports  |   June 1999
The Efficacy of Intrathecal Baclofen in Severe Tetanus
Author Notes
  • (Engrand) Anesthesiologist Resident, Service de Reanimation Polyvalente Hopital Boucicaut, Paris, France.
  • (Guerot) Associate Professor, Service de Reanimation Polyvalente Hopital Boucicaut, Paris, France.
  • (Rouamba) Anesthesiologist, Service de Reanimation Centre Hospitalier National Sanou Souro.
  • (Vilain) ICU Director, Service de Reanimation Centre Hospitalier National Sanou Souro.
  • Received from the Service de Reanimation, Centre Hospitalier National Sanou Souro, Bobo-Dioulasso, Burkina Faso. Submitted for publication July 27, 1998. Accepted for publication January 22, 1999. Support was provided solely from institutional and/or departmental sources. Presented at the 25e congres de la Societe de Reanimation de Langue Francaise, January 22-24, 1997, Paris, France, and the 5e journees des sciences de la sante de Bobo Dioulasso, April 10-13, 1996, Bobo-Dioulasso, Burkina Faso.
  • Address reprint requests to Dr. Engrand: Service de Reanimation polyvalente, Hopital Boucicaut, 78 rue de la Convention, 75015 Paris, France. Address electronic mail to:
Article Information
Case Reports
Case Reports   |   June 1999
The Efficacy of Intrathecal Baclofen in Severe Tetanus
Anesthesiology 6 1999, Vol.90, 1773-1776.. doi:
Anesthesiology 6 1999, Vol.90, 1773-1776.. doi:
Key words: Clostridium tetanii; intubation; mortality.
PROTECTIVE vaccination programs and public health advances have decreased the incidence of tetanus in developed countries. Unfortunately the incidence remains significant in developing countries, with a mortality rate from tetanus of more than 50%, [1] which results in 500,000 deaths per year worldwide. [2] The prognosis of severe tetanus has been improved by critical care units, mechanical ventilation, and the use of neuromuscular blockade. However, this level of care is rarely available in developing countries. As deep sedation and mechanical ventilation are difficult to manage in a tropical environment, many patients die as a result of respiratory distress.
Baclofen, a [Greek small letter gamma]-aminobutyric acid (GABA) receptor agonist, inhibits mono- and polysynaptic medullary reflexes, [3] which results in an antispastic action. The use of baclofen has been proposed as part of the management of tetanus-induced contractures, spinal convulsions, [4] and to limit the need for tracheal intubation [5] in afflicted patients. It has been proven to directly stimulate postsynaptic GABA [Greek small letter beta]-receptors on synapses blocked by tetanus toxin (GABAergic-inhibiting synapses in the anterior cornual of the spinal cord), restoring physiologic inhibition of [Greek small letter alpha] motoneuron.
We report 14 cases of severe tetanus managed with intrathecal baclofen in an African sub-Saharan intensive care unit (ICU). The clinical course of a representative case is presented.
Case Report
A 35-yr-old man (weight, 65 kg) was admitted to our ICU with a 2-day history of severe tetanus (case #13, see Table 2). He had never been immunized with tetanus toxin and had sustained a knee wound 11 days previously. Trismus and dysphagia occurred 8 days after the wound, and generalized spasms occurred 1 day later. On admission, the patient presented with complete lockjaw, neck and general contractures with frequent, severe tonic paroxysms resulting in opisthotonos. He was fully conscious, temperature was 39.3 [degree sign]C, heart rate (HR) was 84 beats/min, and blood pressure was 120/80 mmHg. Dakar score [6] was 3/6 (Table 1). Plasma CPK level was 1,170 U/l (normal value < 100 U/l).
Table 1. Dakar Score* of the Reported Case
Image not available
Table 1. Dakar Score* of the Reported Case
Table 2. Demographic Data, Baclofen Therapy, and Outcome
Image not available
Table 2. Demographic Data, Baclofen Therapy, and Outcome
The knee wound was debrided. The patient was treated with tetanus antitoxin (heterologous serum 1,500 U; Serum antitetanique, Pasteur vaccins, Marnes la Coquette, France), repeated on hospital days 2 and 6, intravenous ampicillin, and vaccinated with tetanus toxin (Tetavax, Merieux, Lyon, France) on days 1, 30, and 60.
Sedation was immediately achieved with intravenous diazepam. An intrathecal catheter (Epidural Minipack, Portex Ltd, UK) was inserted via the L3-L4 vertebral interspace and advanced about 3 cm cephalad. Diazepam administration was ceased, and a bolus of 750 [micro sign]g baclofen (Lioresal, Ciba Geigy, Rueil Malmaison, France; 500 [micro sign]g/ml into saline solution) was administered intrathecally. Paroxysmal contractures disappeared within 2 h of the injection, and the patient was free of rigidity during the next 24 h. A second bolus was administered 24 h after the first one. Because of mild drowsiness during the few hours after injections, a continuous infusion (1,750 [micro sign]g/day) was instituted on the third day. Baclofen was continuously infused from day 3 to day 17 (mean daily dose, 1,690 [micro sign]g), allowing control of muscle rigidity, although trismus persisted. Additional sedation or tracheal intubation was not required. There were no adverse effects except for well-tolerated sinus bradycardia periods (HR, 45 beats/min) from day 12 to day 16.
After 15 days of intrathecal baclofen administration, rigidity was well controlled, and the CPK normalized. The baclofen daily dosage was decreased to 1,500 [micro sign]g and further to 1,000 [micro sign]g on day 17. On day 18, some spasms and moderate neck rigidity reappeared, and temperature increased to 40.5 [degree sign]C and CPK level to 560 U/l. Cerebrospinal fluid (CSF) and blood cultures were positive for Klebsiella pneumoniae. The intrathecal catheter was removed, and ampicillin was switched to ciprofloxacin. Residual muscle rigidity was controlled with diazepam. On day 20, the CSF was sterile, and the CPK level decreased to 143 U/l. Soon afterward the patient rapidly recovered; he was able to walk on day 22 and was discharged from the hospital on day 24.
Additional Data
The ICU is located in Bobo-Dioulasso, Burkina Faso. Mechanical ventilation and neuromuscular blockade are usable, but ventilators and monitors are scarce. Additionally, paramedical staff are less experienced than in developed countries.
From May 1995 to August 1996, 14 patients with severe tetanus (i.e., Dakar score [6] >or= to 2/6 and Mollaret stage [7] II or III) were treated with intrathecal baclofen. Demographic data, main therapeutic modalities, and outcome are summarized in Table 2. All patients received standard tetanus therapy with antibiotics (penicillin, ampicillin), antitoxin, and tetanus immunization. Baclofen administration was started as soon as possible. The dose of the first intrathecal injection was determined according to body weight (500 [micro sign]g if weight < 55 kg; 1,000 [micro sign]g if weight >or= to 55 kg). After administration of the first bolus, continuous intrathecal infusion of baclofen was the preferred method of administration if appropriate equipment was available (baclofen concentration in saline solution ranging from 20 to 80 [micro sign]g/ml). Supplementary intravenous diazepam was used only for extra sedation in those with pain. The dose of baclofen was adjusted every 12 h to allow control of muscle rigidity without adverse effects. If consciousness decreased (Glasgow Coma Score < 13) or bradypnea (respiratory rate < 10 breaths/min) occurred, the infusion was stopped until recovery and then started again at a decreased dose. Intrathecally administered baclofen was continued until persistent resolution of muscular rigidity and then progressively decreased by steps of 500 [micro sign]g every 2 days. The mean baclofen dosage was 1,225 +/- 309 [micro sign]g/day. Mean duration of treatment was 19 +/- 8 days for survivors. When respiratory depression required tracheal intubation, a tracheotomy was performed within 24 h, although there was always an attempt to keep intrathecal baclofen as the only sedation treatment. If intrathecal baclofen failed (lack of resolution of muscle rigidity while severe side effects prohibited dosage increase or respiratory distress required mechanical ventilation), treatment was withdrawn, and general anesthesia was undertaken with mechanical ventilation.
Cerebrospinal fluid cultures were systematically performed at admission and twice a week and additionally when temperature increased to more than 38.5 [degree sign]C. The catheter was removed when a meningeal infection was diagnosed, and baclofen was administered via daily lumbar punctures.
In 12 patients, intrathecal baclofen was effective as antispastic treatment with resolution of generalized muscle rigidity and spasm, although dysphagia and trismus most often persisted. However, two patients (14.3%) had to be intubated because of tracheal obstruction and laryngeal spasm (Table 2). Overall mortality rate was 5 of 14 (35.7%).
These results can be compared with those of the previous 11 patients admitted in our ICU for severe tetanus before the use of intrathecal baclofen. Despite demographic data and severity scores similar to the baclofen-treated patients, 45.5% of these previous patients were intubated, requiring deep sedation in each case. Overall mortality rate was 9 of 11 (81.8%), reaching 100% for intubated patients. These mortality rates are higher than in developed countries (now between 20% [8,9] and 50%, [8,10] depending on age and severity of illness). However mortality is commonly more than 50% in developing countries (up to 74% in Gabon [11]). In such countries, facilities for specialized cares with respect to equipment, medications, and qualified staff are more limited. Although comparison with retrospective controls is difficult, it is our impression that patient outcome is better since the introduction of intrathecal baclofen.
To our knowledge, 26 adults with severe tetanus treated by intrathecal baclofen have been reported to date, [12-22] including 11 cases in Africa. Our series is the largest reported in the literature. Our results agree with the literature, showing efficacy of intrathecal baclofen in controlling muscle rigidity. They also suggest a decreased need for tracheal intubation or deep anesthesia. These findings are important for developing countries wherein intensive care facilities are scarce.
Because of slight liposolubility baclofen does not easily cross the blood brain barrier. Therefore local administration yields to higher concentration on effect site, with fewer adverse systemic effects. After intrathecal injection, the effect of baclofen begins within 1 or 2 h and persists 12-48 h. [5,12] Baclofen elimination half-life in CSF has been found to range from 0.9 to 5 h. [23] After lumbar intrathecal administration, cervical-to-lumbar concentration ratio is 1:4. [24] This distribution probably explains the cephalic progression of hypotonia and the higher posology necessary to relax trismus than legs, which is reported by every author.
The major adverse effect of baclofen is depressed level of consciousness (LOC) and respiratory compromise. [5,25] These potentially deleterious effects can develop at any dose and can develop before resolution of tetanospasm. [22,26] 
Seven of our patients developed decreased LOC or respiratory depression that was readily reversed by decreasing the baclofen dose. This side effect seems more closely related to overdose than to accumulation because it is more often reported after first injections [5] or during bolus administration. [27] 
Three cases of sinus bradycardia were noted, but two of them did not seem to be related to dosage nor to timing of baclofen injection.
Infection of the intrathecal catheter is another serious adverse effects of intrathecal baclofen administration. Meningitis occurred in three patients in our series (patients #2, 13, and 14 on days 5, 8, and 16). However, recovery without sequelae was obtained after withdrawal of the catheter and antibiotic therapy. To avoid these risks, administration by repeated lumbar punctures has been proposed. [15] However, this technique is uncomfortable and also creates the risks of overdose and [28] inability to titrate effect, resulting in consciousness disorders.
Consequently these inherent adverse effects preclude use of this treatment for moderate tetanus that can be managed with benzodiazepine alone without need of tracheal intubation. Nor is intrathecal baclofen appropriate for the most severe forms that need deep sedation and even muscular blockade.
In our 14 patients with severe tetanus, intrathecal baclofen was an efficient treatment allowing effective control of muscle rigidity and spasms in 12 patients and reduced the need for deep sedation in the remaining 2 who required tracheal intubation. These results, which appear to represent an improvement compared with our previous experience and which agree with those previously reported, argue in favor of use of intrathecal baclofen for severe tetanus, especially in developing countries where respiratory resuscitation techniques are seldom available. Further prospective studies comparing intrathecal baclofen with conventional treatment in regard to overall mortality rate, cost, and length of hospital stay are needed.
Bademosi O: Geographical variations in neurological disease-Africa, Oxford Textbook of Medicine, 2nd Edition. Edited by Weatherall DJ, Ledingham JGG, Warrell DA. New York, Oxford University Press, 1990, pp 21, 272-6
Smith MD: Tetanus, Manson's Tropical Diseases, 20th Edition. Edited by Cook GC. London, WB Saunders, 1996, pp 906-13
Curtis DR, Lodge D, Bornstein JC, Peet MJ: Selective effect of baclofen on spinal synaptic transmission in the cat. Exp Brain Res 1981; 42:158-70
Muller H, Borner U, Zierski J, Hempelmann G: Intrathecal baclofen in tetanus (letter). Lancet 1986; 1:317-8
Saissy JM, Demaziere J, Vitris M, Seck M, Marcoux L, Gaye M, Ndiaye M: Treatment of severe tetanus by intrathecal injection of baclofen without artificial ventilation. Intensive Care Med 1992; 18:241-4
Vakil BJ, Bolot JF, Bytchenko B, Femi-Pearse D, Garin JF, Leonardi G, Nair K, Patel JC, Rey M, Sow A, Vic-Dupont V: Proposal for International Classification. Proceedings of the 4th International Conference on Tetanus. Dakar, 1975, pp 6-12
Mollaret P, Vic Dupont V, Cartier F, Margairaz A, Monsallier JF, Pocidalo JJ, Grobglas A: Le traitement du tetanos au centre de reanimation de l'hopital Claude Bernard. Presse Med 1965; 73:2153-6
Prevots R, Sutter RW, Strebel PM, Cochi SL, Hadler S: Tetanus surveillance-United States 1989-1990. MMWR CDC Surveill Summ 1992; 41:1-9
Fleming M, Babcock A, Migliozzi A, Halpin TJ: From the CDC. Tetanus fatality-Ohio 1991 (letter). JAMA 1993; 269:24-31
Pappagallo S, Romagnoli P, Giannoni S, Tinagli F, Feri M, Tulli G: Tetanus disease. Experience with 2 intensive treatments during 13 years. Minerva Anestesiol 1992; 58:165-72
Okome-Kouakou M, Haje A, Ngaka D, Ndinga JP, Sima A: Tetanos a Libreville: analyse hospitaliere de trente-quatre cas. Sante 1997; 7:251-5
Muller H, Borner U, Zierski J, Hempelmann G: Intrathecal baclofen for treatment of tetanus-induced spasticity. Anesthesiology 1987; 66:76-9
Muller H, Zierski J, Borner U, Hempelmann G: Intrathecal baclofen in tetanus. Ann N Y Acad Sci 1988; 531:167-73
Saissy JM, Raux O, Gohard R, Diatta B: Tetanos severe et baclofene intrathecal. Ann Fr Anesth Reanim 1990; 9:183-4
Demaziere J, Saissy JM, Vitris M, Seck M, Marcoux L, Ndiaye M: Intermittent intrathecal baclofen for severe tetanus (letter). Lancet 1991; 1:427
Karp P, Wyss E, Mons P, Fauchart JP, Guillaume JL, Favriel JM: Traitement du tetanos par le baclofene intrathecal (letter). Rean Soins Intens Med Urg 1991; 7:304
Saissy JM, Vitris M, Demaziere J, Seck M, Marcoux L, Gaye M: Flumazenil counteracts intrathecal baclofen-induced central nervous system depression in tetanus. Anesthesiology 1992; 76:1051-3
Pellanda A, Caldiroli D, Vaghi GM, Bonelli S: Treatment of severe tetanus by intrathecal infusion of baclofen (letter). Intensive Care Med 1993; 19:59-60
Sicignano A, Lorini FL: Does flumazenil antagonize baclofen? (letter). Intensive Care Med 1994; 20:533
Brok H, Moosbauer W, Gabriel C, Necek S: Treatment of severe tetanus by continuous intrathecal infusion of baclofen (letter). J Neurol Neurosurg Psychiatry 1995; 59:193-4
Francois B, Clavel M, Desachy A, Vignon P, Salle JY, Gastinne H: Injection intrathecale continue de baclofene en cas de tetanos generalise. Presse Med 1997; 26:1045-7
Dressnandt J, Konstanzer A, Weinzierl FX, Pfab R, Klingelhofer J: Intrathecal baclofen in tetanus: Four cases and a review of reported cases. Intensive Care Med 1997; 23:896-902
Sallerin-Caute B, Lazorthes Y, Monsarrat B, Cros J, Bastide R: CSF baclofen levels after intrathecal administration in severe spasticity. Eur J Clin Pharmacol 1991; 40:363-5
Penn RD, Kroin JS: Intrathecal baclofen (letter). N Engl J Med 1989; 321:1414-5
Muller H, Zierski J, Dralle D, Hoffman O, Michaelis G: Intrathecal baclofen in spasticity, Local Spinal Therapy of Spasticity. Edited by Muller H, Zierski J, Penn RD. Berlin-Heidelberg, Springer-Verlag, 1988, pp 154-214
Romijn JA, Vanlieshout JJ, Velis DN: Reversible coma due to intrathecal baclofen (letter). Lancet 1986; 2:696
Penn RD: Chronic intrathecal baclofen for severe rigidity and spasm, Local-Spinal Therapy of Spasticity. Edited by Muller H, Zierski J, Penn RD. Berlin-Heidelberg, Springer-Verlag, 1988, pp 151-3
Silbert PL, Stolp-smith KA: Intrathecal baclofen in tetanus: Alternative methods of administration (letter). Anesthesiology 1993; 79:199-200
Table 1. Dakar Score* of the Reported Case
Image not available
Table 1. Dakar Score* of the Reported Case
Table 2. Demographic Data, Baclofen Therapy, and Outcome
Image not available
Table 2. Demographic Data, Baclofen Therapy, and Outcome